The Courage to Continue: the Staphylococcus aureus Network Adaptive Platform Trial for Pediatrics and Youth

Authors
Category Primary study
JournalJournal of the Pediatric Infectious Diseases Society
Year 2026
Lay Summary: The Staphylococcus aureus Network Adaptive Platform trial is a whole-of-life infectious disease trial. Recently, results for the methicillin-susceptible Staphylococcus aureus domain in adults showed cefazolin is non-inferior to (flu)cloxacillin for S. aureus bacteremia. The trial continues in children. Here the investigators outline why.
Epistemonikos ID: c61d02eb0cf03a5b458dddb23ba2dcb6c4161d70
First added on: Aug 14, 2026